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Abstract
Background: Occipital nerve stimulation (ONS) has raised new hope for drug-resistant chronic cluster headache
(drCCH), a devastating condition. However its mode of action remains elusive. Since the long delay to meaningful
effect suggests that ONS induces slow neuromodulation, we have searched for changes in central pain-control
areas using metabolic neuroimaging.
Methods: Ten drCCH patients underwent an
18FDG-PET scan after ONS, at delays varying between 0 and 30
months. All were scanned with ongoing ONS (ON) and with the stimulator switched OFF.
Results: After 6-30 months of ONS, 3 patients were pain free and 4 had a ≥ 90% reduction of attack frequency
(responders). In all patients compared to controls, several areas of the pain matrix showed hypermetabolism:
ipsilateral hypothalamus, midbrain and ipsilateral lower pons. All normalized after ONS, except for the
hypothalamus. Switching the stimulator ON or OFF had little influence on brain glucose metabolism. The
perigenual anterior cingulate cortex (PACC) was hyperactive in ONS responders compared to non-responders.
Conclusions: Metabolic normalization in the pain neuromatrix and lack of short-term changes induced by the
stimulation might support the hypothesis that ONS acts in drCCH through slow neuromodulatory processes.
Selective activation in responders of PACC, a pivotal structure in the endogenous opioid system, suggests that ONS
could restore balance within dysfunctioning pain control centres. That ONS is nothing but a symptomatic
treatment might be illustrated by the persistent hypothalamic hypermetabolism, which could explain why
autonomic attacks may persist despite pain relief and why cluster attacks recur shortly after stimulator arrest. PET
studies on larger samples are warranted to confirm these first results.
Background
Cluster headache (CH) is one of the most painful pri-
mary headaches and is characterized by attacks of severe
unilateral periorbital pain associated with ipsilateral
autonomic features [1]. About 10% of patients have, or
develop over time, a chronic form (CCH) [2] charac-
terised by recurrent attacks for at least 1 year without
r e m i s s i o n so rw i t hr e m i s s i o n so fl e s st h a n1m o n t h[ 1 ] .
About 1% of CCH patients become drug-resistant
(drCCH) to most prophylactic drug treatments and fulfil
published criteria for intractable headaches [3].
CH is the most prevalent member of the so-called
trigeminal autonomic cephalalgias (TACs), which
include paroxysmal hemicrania, SUNCT (Short-lasting
Unilateral Neuralgiform headache with Conjunctival
injection and Tearing) and probably hemicrania conti-
nua [4]. Neuroimaging studies have provided new
insight into the pathophysiology of these disorders.
Besides non-specific changes in activity of brain areas
belonging to the pain matrix like the anterior cingular
cortex (ACC), insula(e), and thalamus, TACs are asso-
ciated with ictal activation of ipsilateral posterior
hypothalamus (CH, SUNCT) or dorsal pons
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hypothalamus (paroxysmal hemicrania) which may be
more specific and disease-related [5].
As a consequence, deep brain stimulation (DBS) tar-
geting the posterior hypothalamus was proposed for
drCCH and was found to be more effective than any
previously used invasive therapy [6,7]. However
hypothalamic DBS is not a riskless procedure [7] and
less invasive methods were thus explored. Among them,
occipital nerve stimulation (ONS) had comparable effi-
cacy to hypothalamic DBS, except for slower onset of
action [8,9].
The mechanisms by which ONS improves drCCH
remain unclear. In a study of ONS in drCCH we found
no significant change in pain thresholds, which argues
against a diffuse analgesic effect [8]. It was speculated
that ONS might exert its action by decreasing excitabil-
ity of second order nociceptors in trigeminal nucleus
caudalis on which converge cervical, somatic trigeminal
and visceral trigeminovascular afferents [10,11]. Yet, the
nociception-specific blink reflex, mediated by spinal tri-
geminal nucleus interneurons, was increased rather than
decreased in our study of ONS in drCCH [8] and it
remained unchanged in healthy subjects after short low
frequency transcutaneous stimulation of the greater
occipital nerve [12]. A more likely explanation for the
therapeutic effect of ONS in headache including drCCH
is the induction of slow neuromodulatory changes in
brain regions belonging to the pain matrix or in centres
more specifically involved in CCH pathophysiology.
Hence, chronic migraine patients treated with ONS [13]
show significant blood flow increases on H2
15O-PET in
dorsal rostral pons, anterior cingulate cortex and
cuneus, directly correlated to pain scores, and in left
pulvinar, inversely correlated to such scores. Dorsal
pons activation persisted after ONS, supporting the role
of this structure in migraine pathophysiology [13].
So far, functional imaging studies have not been per-
formed in ONS-treated drCCH patients. We performed
such a study focusing on the pain matrix, but also on
hypothalamus and brainstem that seem more specifically
involved in the pathophysiology of TACs. We enrolled
patients from the published cohort [8] and newly
implanted ones. We used 18-fluorodeoxyglucose-posi-
tron emission tomography (18-FDG-PET) in order to
detect long term activity modulation.
Methods
Subjects
We studied 10 patients with drCCH (9 males and 1
female, mean age at implantation 44.2 ± 9.9 years SD).
Inclusion criteria were: CCH for at least 2 years, daily
attacks by history, side-locked attacks from the begin-
ning, resistance to drug treatment according to expert
consensus guidelines [3] and absence of associated dis-
abling organic or psychiatric disorder. Five patients had
left-sided, 5 right-sided attacks. At the time of the study,
all patients were taking one or several of the following
preventive drugs: verapamil (n = 9), lithium carbonate
(n = 6), methylprednisolone (n = 2), methysergide (n =
2), melatonine (n = 1), gabapentine (n = 1). None took
analgesics, in particular opioids.
Patients were recruited in two phases (1
st and 2
nd
group), with written informed consent. Approval of the
local Ethics Committee for ONS in drCCH was first
obtained for 5 patients (EUDRACT-2004-004551-19).
Because of the favourable results in ONS-treated patients
after a 16 months follow-up, we requested Ethics Com-
mittee approval for a protocol amendment allowing us to
recruit 6 supplementary patients who were implanted
and agreed to undergo PET before and after surgery. At
the same time, patients of the 1
st group were also asked
to participate in the PET study and 4 of them accepted
(the last patient of group 1 had been explanted [8]).
Surgical and stimulation procedure
Surgical procedure and stimulation protocols have been
described previously [8]. We used unilateral subcuta-
neous implantation of paddle style stimulating leads
with 4 electrode plots (Medtronic 3587A Resume II
®;
Medtronic Inc., Minneapolis, USA) via a retromastoid
C1-2-3 approach [14] and Medtronic Itrel III
® or
Synergy
® stimulators.
Stimulation protocols were adapted using a program-
ming matrix [8] such as to induce paraesthesias in the
largest possible occipital territory. The clinical evolution
of patients was monitored with cluster headache paper
diaries.
18-FDG-PET study design
Study groups
In the 1
st group, patients (n = 4), underwent a PET ses-
sion after 24 to 30 months of ONS. All patients but one
belonging to the 2
nd group (n = 6) were scanned before
implantation (baseline). In both groups, for each session
after implantation, patients were scanned with the sti-
mulator switched on (ON) and off for 3 days (OFF).
This period was arbitrarily fixed in line with our pre-
vious observation of headache recurrence within 2 days
on average after switching off the stimulator [8]. They
underwent 2 more pairs of scans after 1 and 6 months
of ONS. None of the patients had a cluster attack dur-
ing PET, nor within the 12 hours preceding or following
the procedure.
Data collected in patients were compared to a pool of
39 drug-free healthy volunteers (HV) (18 males, 21
females, mean age 45 ± 16 years SD) without headache
history.
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PET data were obtained on a Siemens CTI 951 16/32
®
scanner (Siemens, Erlangen). Data were corrected for
attenuation and background activity. Resting cerebral
metabolism was studied after intravenous injection of 5-
10 mCi (185-370 MBq) [18F]fluorodeoxyglucose (FDG).
Subjects were scanned in a dark room, with minimal
environmental noise.
Statistical analysis (Cyclotron Research Centre, Liège)
Because we selected CH patients with side-locked uni-
lateral attacks and as there was no side shift during the
observational period, we flipped the PET scans of the
patients with right-sided symptoms in the axial plane so
that we could analyze all subjects together (all “left-
sided”). We used a binary classification of patients
responding or not to ONS with an arbitrary, but clini-
cally relevant, cut-off point for responders set at 50%
decrease in attack frequency. Given the data from pre-
vious functional imaging studies, we conducted our ana-
lysis with an a priori hypothesis towards regions known
to be involved in CH and other TACs [5], areas which
are modulated by ONS in chronic migraine [13] and
areas belonging to the pain matrix.
Data were analysed using statistical parametric map-
ping (SPM8 version; Wellcome Department of Cognitive
Neurology Institute of Neurology, London, UK; http://
www.fil.ion.ucl.ac.uk/spm) implemented in MATLAB
(version 7.1, MathworksInc., Sherborn, MA). Images
were spatially normalized into a standard stereotactic
space using a symmetrical MNI (Montreal Neurological
Institute) PET template [15] and smoothed using a 14
mm full-width-half-maximum (FWHM) isotropic kernel
[16]. T-test was used with a significance level set at p <
0.001 uncorrected (p < 0.05 FDR).
The first design matrix included the scans of the 39
HV, of the 4 patients of the 1
st group performed 24 to 30
months post-ONS and of the 6 patients of the 2
nd group,
scanned before implantation (baseline), 1 month and 6
months post-ONS. Our first analysis identified brain
regions with a significant hyper- or hypometabolism in
drCCH patients as compared to HV independent on time
of scanning or ONS stimulation. Then, we looked for
brain regions showing short term ONS-induced (ON ver-
sus OFF) increase or decrease in metabolism indepen-
dent on delay since ONS implantation, in the early post-
ONS phase (scans obtained after 1 month) and in the
late post-ONS phase (scans obtained after 6 and 24-30
months). Finally, we compared metabolic activity mea-
sured during baseline, early phase (1 month) and late
phase (≥ 6 months) post-ONS (independent of ONS sti-
mulator settings) searching for progressive increases and
decreases in metabolism over time.
In a second design matrix we searched for differences
between the subgroups of 7 responders and 3 non-
responders. Here, we included only the PET data
obtained in the late phase (≥ 6 months; both with sti-
mulator ON and OFF) and the HV scans, searching for
regions with metabolic differences between the two
groups (i.e., increased metabolism - as compared to HV
- present in responders but not in non-responders).
For all analyses, the resulting set of voxel values for
each contrast, constituting an SPM of the t-statistics
(SPM{t}), was transformed to the unit normal distribu-
tion (SPM{Z}) and thresholded at p = 0.001. All group
results were thresholded at false discovery-corrected p <
0.05, corrected for the whole brain volume. For differ-
ences between responder and non-responder subgroups,
results were corrected for multiple comparisons within
the regions of interest identified during the previous
whole group analyses by employing a small volume cor-
rection (10 mm radius sphere).
Results
Clinical outcome
Clinical data of patients and changes in their attack fre-
quency after various durations of ONS are summarized
in table 1. All patients but one in the 1
st group (N = 4,
24-30 months follow-up) improved after ONS: one
patient was pain free; 2 patients had a 90% and 93%
reduction in attack frequency; the “non-responder”
patient had a 25% improvement. In the 2
nd group (N =
6), at 6 months follow-up, 3 patients were pain free and
one was improved by 90%; these 4 patients already
reported significant improvement after 1 month of
ONS. The 5
th patient only had a 33% reduction in attack
frequency while in the 6
th patient, attack frequency was
slightly increased. According to the 50% cut-off criter-
ion, 7 patients were thus considered responders and 3
non-responders to ONS for the binary analysis. During
the 3-day period of ONS interruption, only one respon-
der had recurrence of attacks. In the 2
nd group, all
patients kept the same preventive drug treatment during
the follow-up scans except for one responder (8) who
was able stop all medications after 6 months.
PET results
The main areas of peak voxels where a metabolic
change was found for the various comparisons are
shown in table 2.
We first pooled all scans performed in drCCH patients
and compared them with those of the HV. In comparison
t oH V ,as i g n i f i c a n th y p e r m e t a b o l i s mw a sf o u n di na n t e r i o r
cingulate cortex (ACC), left hypothalamus, left pulvinar,
left visual cortex, cerebellum and brain stem (left lower
pons and midbrain) (figure 1). By contrast, a significant
hypometabolism appeared in both sensori-motor areas.
There was no significant difference between scans per-
formed with stimulator ON or OFF, regardless of ONS
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Patients Age Cluster &
ONS side
Average number of attacks/
last 4 weeks
% reduction
in attack frequency
ONS
responder
BEFORE
ONS
24-30 mths
ONS
24-30 mths
ONS
Group 1
1 48 R 131.6 98.0 26 N
2 46 L 107.6 7.6 93 Y
3 32 R 32.4 3.2 90 Y
4 53 L 28.0 0.0 100 Y
BEFORE
ONS
1 month
ONS
6 months
ONS
1 month
ONS
6 months
ONS
Group 2
5 31 R 28.0 7.2 0.0 74 100 Y
6 60 R 28.0 7.2 2.8 74 90 Y
7 47 L 112.0 92.4 116.4 17.5 -4 N
8 50 R 42.0 4.4 0.0 80 100 Y
9 31 L 56.0 2.0 0.0 97 100 Y
10 44 L 16.4 13.2 11.2 22 33 N
ONS: occipital nerve stimulation, R: right, L: left, Y: yes, N: no.
Table 2 Main statistical results and localization of peak voxels where cerebral metabolism was activated (>) or
deactivated (<)
Analysis Brain region Talairach coordinates Z score of peak p FDR corrected
xyz
drCCH > HV ACC 12 40 -4 5 < 0.001
Perigenual ACC -8 28 -8 5.29 < 0.001
Midcingulate 12 20 30 4.07 0.003
Left visual cortex -10 -98 -8 3.43 0.010
Left pulvinar -16 -36 8 4.49 0.001
Left hypothalamus -2 -12 -16 2.71 0.013
Cerebellum -16 -36 46 4.28 0.002
Midbrain 2 -34 -4 3.53 0.008
Left lower pons -8 -32 -46 4.13 0.003
drCCH < HV R/L Sensorimotor -58 -34 -18 4.43 0.012
58 -18 -26 4.42 0.012
-4 -22 70 4.26 0.012
-25 -22 66 3.73 0.015
-6 -24 68 3.37 0.025
Right prefrontal 42 26 24 3.76 0.015
Base > ONS ACC -8 28 -8 4.66 0.003
Midcingulate 12 20 30 3.75 0.013
Left visual cortex -10 -98 -10 3.25 0.031
Left pulvinar -18 -38 6 3.8 0.012
Cerebellum 2 -42 -16 3.67 0.015
Midbrain 2 -40 -12 3.63 0.016
Left lower pons -8 -30 -44 4.40 0.024
Base < ONS R/L Sensorimotor -58 -34 -18 4.59 0.013
58 -18 -26 4.26 0.037
42 26 24 3.75 0.026
-4 -22 70 3.78 0.029
Resp > non resp Perigenual ACC -8 28 -8 4.01 0.002*
Coordinates are in the standardized stereotactic Montreal Neurological Institute space (mm). FDR = False discovery rate corrected. drCCH: drug-resistant chronic
cluster headache; HV: healthy volunteers; ACC: anterior cingulate cortex, R: right, L: left. * FDR corrected in region of interest identified in whole group analysis.
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t h el a t ep h a s e( ≥ 6 months) we observed a hypermeta-
bolism in the left frontal lobe (BA 10, uncorrected p =
0.03, x = -12, y = 46, z = 4) and the left lower brainstem
(uncorrected p = 0.014, x = -6, y = -30, z = -36) when
the stimulator was turned ON, but these results,
reported for the sake of completeness, did not survive
correction for multiple comparisons.
Over time, ONS changed glucose uptake in several
brain areas (independent of the stimulator settings ON
or OFF). The anterior cingulate, mid cingulate, left pulvi-
nar, midbrain, lower pons, visual cortex and cerebellum
had decreased metabolism over time, i.e. they became
less hypermetabolic when comparing baseline to the
early phase (1 month) or the late phase (≥ 6m o n t h s ) .B y
contrast, metabolism increased over time in sensorimotor
cortices, i.e. they became less hypometabolic, and it was
not modified in the left hypothalamus (figure 2).
When finally comparing responders and non-respon-
ders in the late phase, there was a significant hyperme-
tabolism in previously identified perigenual ACC
ipsilateral to the pain and stimulation side in responders
(figure 3). No hypometabolic area differentiated respon-
ders from non-responders.
C
ACC
MB
LP
VC ACC
C
P
H
Midline (X= 5) Left  (X= -12)
C
ACC
MB
LP
VC ACC
C
P
H
Z score
Figure 1 Hypermetabolic areas in drCCH patients (all conditions: baseline - 1 month, 6 months, 24/30 months) compared with HV (p
< 0.05 FDR corrected). Results are displayed on 2 sagittal sections of a normalized MRI template (through midline and left hemisphere). ACC:
anterior cingulate cortex, C: cerebellum, MB: midbrain, LP: lower pons, VC: visual cortex, P: pulvinar, H: hypothalamus.
C
ACC VC ACC P
C
B
Right (X= 12) Left  (X= -10)
C
ACC VC ACC P
C
B
Z score
Figure 2 Areas progressively deactivated by ONS over time (p < 0.05 FDR corrected).R e s u l t sa r ed i s p l a y e do n2 sagittal sections of a
normalized MRI template (right and left hemisphere). ACC: anterior cingulate cortex, C: cerebellum, B: brainstem, VC: visual cortex, P: pulvinar.
White circle highlights hypothalamic area, which is not modified by the stimulation.
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The therapeutic outcome after ONS in 1
st and 2
nd groups
was overall similar, with good response as defined above
in nearly 70% of patients [8,17]. A noticeable difference
between the 2 groups was the latency to significant effi-
cacy, which was on average shortened to 1 month in the
2
nd g r o u pc o m p a r e dt o3m o n t h si nt h e1
st one. This
remains compatible with a slow modulatory effect on the
central nervous system. We ascribe faster efficacy in
group 2 to a learning effect for investigators and to
quicker optimisation of stimulator settings [8].
We will focus our discussion on the FDG-PET
findings.
PET findings - interpretation
Metabolic pattern in drCCH compared to HV
The enhanced FDG uptake found ipsilaterally in hypotha-
lamus of drCCH patients respective to HV is in line with
the reports showing increased activity in this area with
H2
15O-PET or fMRI during attacks [18-20]. However in
our study all patients were scanned between attacks, i.e. at
a time point when hypothalamic activation has not been
reported yet. Another FDG-PET study of episodic CH
comparing patients during and between bouts revealed no
change in hypothalamic glucose uptake [21].
Areas belonging to the pain matrix like the cingulate
gyrus or midbrain (periaqueductal grey - PAG) are clas-
sically activated in various pain states including head-
aches [5]. We also found activation in the cerebellum, in
line with previous imaging studies showing consistent
cerebellar activation across the spectrum of pain from
visceral to somatic, acute to chronic [22]. Activation of
cerebellar vermis and anterior lobe in drCCH may be
particularly strong due to dense somatotopically
arranged trigemino-cerebellar connexions [22], but also
because there are direct connections between the ven-
tro-posterior hypothalamic area and the cerebellum as
shown by MRI tractography in a drCCH patient treated
with hypothalamic DBS [23].
The perigenual ACC (PACC) is of particular interest.
Contrary to our results, it was found hypometabolic
compared to HV in episodic CH [21]. However, when
the authors compared the same patients during and
between bouts, the PACC was hypermetabolic during
the bout despite the absence of an attack at the time of
scanning.
Lower pons activation has been described during
attacks of hemicrania continua, but not of CH [5]. In
hemicrania continua, dorsal pontine activation is ipsilat-
eral, like in our study, while posterior hypothalamic acti-
vation is observed on the opposite side, unlike in CH.
The pulvinar where we found ipsilateral activation in
drCCH patients has not been a region of interest in CH
before. Pulvinotomy and electrical stimulation of the
pulvinar have been used successfully in the treatment of
chronic pain in humans [24]. In functional neuroima-
ging studies, pulvinar hypermetabolism is either asso-
ciated with pain state [25] or with pain relief after
various procedures [24], including ONS in chronic
migraine [13].
We have no straightforward explanation for the
increased metabolism of the ipsilateral visual cortex in
our patients. Such activation has not been reported
hitherto. Photophobia ipsilateral to the pain is a fre-
quent attack-associated symptom in various TACs, in
particular CH [26]. Like in migraineurs, the visual cortex
of CH patients might thus be more sensitive to light sti-
muli. This hypothesis seems unlikely, however, as all
subjects were scanned in a dark room.
To summarize, the interictal FDG-PET hyperactive
pattern of drCCH patients comprises areas reported to
be hypermetabolic mainly during TAC attacks (ipsilat-
eral hypothalamus and pons), but also during a bout of
the disorder outside of an attack (perigenual ACC).
Short-term changes associated with ONS
We found no significant differences between PET
recordings performed with stimulator ON or OFF
within a 72 hour delay. This finding is similar to
Matharu et al.’s [13] observations in chronic migraine,
except that they were not able to scan the patients OFF
and pain-free because of an almost immediate recur-
rence of pain after interrupting the stimulation. They
concluded that central structures were not modulated in
c h r o n i cm i g r a i n eb yO N Sb e y o n dt h es t i m u l a t i o n
period.
Here, lack of short-term metabolic modification
favours a slow neuromodulatory effect of ONS, as we
Left  (X= -8)
Z score
Figure 3 Activation of perigenual cortex in ONS responders vs.
non responders after 6 to 30 months stimulation (p < 0.05
FDR corrected). Result is displayed on a left sagittal section of a
normalized MRI template.
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ted with hypothalamic DBS, May et al. [27] found rapid
metabolic changes with H2
15O-PET in various brain
structures involved in cluster headache and more gener-
ally in the pain matrix within only 10 minutes of switch-
ing the stimulator ON or OFF, but there were no
clinical correlates suggesting that the therapeutic effect
of DBS is also due to slow CNS changes.
Our subanalysis with a smaller significance level revealed
a change in left lower brainstem metabolism. It might
indicate a short term ONS effect in the trigemino-cervical
complex. As expected from the neuro-anatomical connex-
ions, the trigemino-cervical complex could relay stimula-
tion to more rostral structures allowing for neuroplastic
modulation of their activity. In comparison, a recent study
of transcutaneous electrical nerve stimulation (TENS) in
arthritic rats suggests that its antinociceptive effect is
mediated by ascending activation of the opioid system ori-
ginating in the ventrolateral PAG and projecting via the
rostral ventro-medial medulla to the spinal cord [28].
Long-term changes associated with ONS
Hypermetabolism of most overactive areas in drCCH
patients compared to HV decreased after ONS. This was
particularly obvious for the anterior cingulate cortex, left
pulvinar, left visual cortex, left lower pons, cerebellum
and midbrain. Conversely, baseline hypometabolism of
sensori-motor cortices increased after ONS. The note-
worthy exception to these post-ONS metabolic changes
is the ipsilateral hypothalamus. This is precisely the
region activated during CH attacks on the side of the
pain [18] and where increased gray matter density is
found on voxel-based MRI between attacks [29]. Our
findings in drCCH contrast with those by Sprenger et al
[21] in episodic CH where no significant metabolic
change was found in the hypothalamus, either outside or
during the bout. If replicated, our data suggest that per-
sistent hypothalamic activation is a hallmark of chronic
CH. They may explain why attacks are non-remittent but
also why some ONS-treated, pain-free patients still have
autonomic attacks [8]. A similar conclusion was drawn
for the dorsal rostral pons in chronic migraine following
the finding of persistent activation in this area despite
ONS-induced pain relief [13]. The persistence of an ipsi-
lateral hypothalamic activation despite reduced attack
frequency also confirms that ONS is no more than a
symptomatic therapy, as already suggested by the recur-
rence of attacks after interruption of the stimulation [8].
The metabolic changes observed after ONS could be
due to the stimulation itself or to the reduction of attack
frequency. Our protocol did not allow to favour either
mechanism. However, despite the small number of non-
responders in our study, some insight might be gained
from the comparison of patients who clearly responded
to ONS and those who did not.
Perigenual ACC (PACC) activation in responders
Comparison of ONS responders and non-responders
revealed increased FDG uptake in the PACC of the for-
mer. This area is of interest for several reasons. First,
PACC plays a major role in central opioidergic pain con-
trol system. It is selectively activated during analgesia
induced by the μ-receptor agonists fentanyl and remifen-
tanyl compared with placebo [30], providing evidence
that opioidergic analgesia is mediated by activation of
descending antinociceptive pathways. Second, PACC was
found hypometabolic respective to HV in episodic CH,
but its activity increased significantly during the bout
[21]. Knowing the pivotal role of PACC in descending
pain control, these authors hypothesized that deficient
endogenous antinociceptive mechanisms between bouts
might predispose CH patients to the disorder and to its
recurrence. Concordantly, Sprenger et al [31], using PET
with the opioidergic ligand [11C]diprenorphine, demon-
strated an inverse linear relationship between the dura-
tion of CH and opioid receptor availability in the rostral
ACC (and ipsilateral hypothalamus). A recent case report
by the same group of a drCCH patient in whom low dose
levomethadone induced complete remission of attacks
favours this hypothesis [32].
Compared to TENS that was shown to induce analge-
sia through activation of a PAG-RVM-spinal cord path-
way [28], ONS could activate this descending pain-
control pathway even further up-stream at the level of
PACC. Its therapeutic effect in drCCH patients could
thus be due to progressive restoration of activity in defi-
cient opioidergic antinociceptive pathways.
Study limitations
We are well aware of some methodological flaws that
may limit the strength of our findings.
First, the number of patients included is rather small.
This is the case in most similar studies as drCCH
patients are rare and ONS is an emerging treatment
modality for which only 38 cases, including ours, have
been published. In a much commoner condition like
chronic migraine, metabolic imaging studies have been
limited to less than 10 patients [13].
A second shortcoming is the dichotomy of the PET
design. PET studies were not planned in our initial pilot
study of ONS in 5 patients as the outcome was uncer-
tain and the sample considered too small. As clinical
efficacy was encouraging, we were allowed to recruit 6
additional patients, for whom imaging studies were
planned prospectively. For greater sample size, patients
from the 1
st group were also proposed to undergo PET.
This explains why the latter had neither baseline nor 1
month scans and why long-term treatment periods vary
between 6 and 30 months. We know since that there is
no further clinical improvement after 6 months of ONS
and that in most patients attacks recur after stimulation
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why we decide to merge scans obtained between 6 and
30 months of ONS, albeit statistically questionable.
Finally, one may argue that the prophylactic drugs
taken by the patients may have influenced the PET
results. This cannot be ruled out, as HV did not take
any medication. However, pharmacotherapy remained
stable in all patients of the 2
nd group except one and
was similar in ONS responders and non-responders.
Conclusions
We confirm that ONS is effective and safe in drCCH,
reducing attack frequency by ≥ 50% in more than 60%
of patients, which is similar to the results obtained with
hypothalamic DBS.
The FDG-PET results in our small sample appear con-
sistent with the clinical impression that ONS exerts its
beneficial effects via slow neuromodulatory processes in
the central pain matrix. The finding of a possible selec-
tive perigenual ACC activation in responders compared
to non-responders might advocate that ONS activates
descending pain control systems in a top-down manner
and restores an equilibrium in anti-nociceptive opioider-
gic pathways. We suggest for the first time that meta-
bolic activity could be increased in ipsilateral posterior
hypothalamus in chronic cluster headache patients out-
side of an attack. That ONS, as suspected on clinical
grounds, does not cure drCCH, but merely acts as a
symptomatic treatment is underlined by its inability to
reduce this ipsilateral hypothalamic hyperactivity which
is typically found during attacks in episodic cluster
headache. Persistent hypothalamic activation might also
explain why ONS-treated pain-free drCCH patients may
still have autonomic attacks and why attacks rapidly
recur after interruption of ONS.
Abbreviations used in the text
18-FDG-PET: 18-Fluorodeoxyglucose-positron emission tomography; ACC:
anterior cingular cortex; BA: Brodmann area; DBS: deep brain stimulation;
drCCH: drug-resistant chronic cluster headache; HV: healthy volunteers; OFF:
stimulator switched off; ON: stimulator switched on; ONS: occipital nerve
stimulation; PACC: perigenual anterior cingular cortex; PAG: periaqueductal
grey; TACs: trigeminal autonomic cephalalgias; TENS: transcutaneous
electrical nerve stimulation
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